# CCTG CE.6 / EORTC 26062-22061 (Perry trial)

Source: https://onco.cc/trials/cctg-ce6/  
OnCo record `cctg-ce6` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that set treatment for older patients with glioblastoma: three weeks of radiotherapy instead of six, with temozolomide added, extended survival without worsening quality of life.

## Summary

CCTG CE.6 with EORTC 26062-22061 and TROG 08.02, trial NCT00482677, randomised 562 patients aged 65 or older (median 73) with newly diagnosed glioblastoma to short-course radiotherapy (40 Gy in 15 fractions) with or without concurrent and adjuvant temozolomide. Median overall survival was 9.3 versus 7.6 months (HR 0.67, 95% CI 0.56-0.80) and median progression-free survival 5.3 versus 3.9 months; with a methylated MGMT promoter, 13.5 versus 7.7 months (HR 0.53), and with an unmethylated promoter 10.0 versus 7.9 months (HR 0.75, 95% CI 0.56-1.01). Quality of life was similar in the two arms. Published by Perry and colleagues in NEJM in 2017. Two earlier trials had established the alternatives for older or frail patients: the Nordic trial (Malmström 2012; temozolomide alone or hypofractionated radiotherapy at least as good as standard six-week radiotherapy over age 60, and better over 70) and NOA-08 (Wick 2012; temozolomide alone non-inferior to radiotherapy alone, with MGMT methylation predicting who benefits from temozolomide).

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Registry id: NCT00482677
- Phase: 3
- Setting: Newly diagnosed glioblastoma, age 65 or older: short-course radiotherapy (40 Gy in 15 fractions) with concurrent and adjuvant temozolomide vs short-course radiotherapy alone
- Sponsor: Canadian Cancer Trials Group / EORTC / TROG
- Enrolled: 562
- Result: OS 9.3 vs 7.6 months, HR 0.67 (95% CI 0.56-0.80).
- Outcomes: Overall survival, age 65 or older: Short-course RT + temozolomide 9.3 months vs Short-course RT alone 7.6 months, HR 0.67
- Replication: Single randomised trial of adding temozolomide to short-course radiotherapy; the Nordic and NOA-08 trials support hypofractionated radiotherapy or temozolomide alone in older patients, with MGMT status guiding the choice.

## Sources

- ClinicalTrials.gov NCT00482677: https://clinicaltrials.gov/study/NCT00482677
- Perry et al., Short-course radiation plus temozolomide in elderly patients with glioblastoma (NEJM 2017): https://doi.org/10.1056/NEJMoa1611977
- Malmström et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (Lancet Oncology 2012): https://doi.org/10.1016/S1470-2045(12)70265-6
- Wick et al., Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial (Lancet Oncology 2012): https://doi.org/10.1016/S1470-2045(12)70164-X

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- terms: [MGMT promoter methylation](https://onco.cc/terms/mgmt/)

---
JSON: https://onco.cc/api/v1/entities/cctg-ce6.json